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ABSTRACT: The ﬁeld of reproductive medicine has been criticized for introducing ARTs without systematic research on possible safety risks
and for failing to meet the standards of evidence-based innovation held elsewhere in medicine. In this paper, ﬁrstly, we ask whether ‘responsible
innovation’ has been a concern for the ﬁeld, and if so, how it has understood the practical implications of this idea for the development and
introduction of potentially risky new ARTs. Secondly, we consider whether the ﬁeld has indeed fallen short of its responsibilities in this respect,
and if so, how things can be improved. To answer these questions, we present three case studies involving the introduction of a new reproductive
technology: ICSI, preimplantation genetic testing and mitochondrial replacement therapy. As a framework for analyzing these cases, we used
Per Sandin’s account of the four dimensions of dealing with risks (threat, uncertainty, action, command) that are central to debates about
the possible role of the so-called precautionary principle. We conclude that, although offspring safety concerns have been on the agenda of
the debate about bringing the relevant technologies to the clinic, systematic safety and effectiveness studies were not always conducted. As
professionals in assisted reproduction have a responsibility to take account of the welfare of the children they are creating, we suggest a policy
of proceeding with systematic caution. Legal measures may be needed to ensure that professional guidance is followed in practice. Finally, an
open question concerns the threshold for acceptable risk in the context of introducing new ARTs. Multiple stakeholders, including professional
societies and patient organizations, should have a role in the urgent debate about this.
Key words: reproductive medicine / responsible innovation / precaution principle / ICSI / preimplantation genetic testing / mitochondrial
replacement therapy / ART
Introduction
One concern within the wide range of ethical questions pertaining to
developments in reproductive medicine is whether treatment safety is
sufficiently taken seriously when introducing new ARTs (Pennings et al.,
2007; Van Steirteghem, 2008; Harper et al., 2012; Provoost et al., 2014;
Mulder et al., 2018; Sharpe, 2018). Several commentators have pointed
out that ARTs have often been, and are still being, introduced without
systematic preclinical safety and effectiveness studies and without
follow-up of children conceived with those technologies (Dondorp and
de Wert, 2011; Harper et al., 2012, 2017; Sharpe, 2018). Although
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safety and effectiveness are different things, it is important to note
that where evidence of effectiveness is lacking, there are no clear
beneﬁts that might render possible risks worth taking. In other words,
to determine the proportionality of potentially risky new ARTs, data
about safety and effectiveness are both needed.
This critique that these data have not systematically been sought
invites two different kinds of question. Empirically, the question is
whether ‘responsible innovation’ has been a concern for the ﬁeld, and
if so, how it has understood the practical implications of this idea
for the development and introduction of potentially risky new ARTs.
Ethically, the question is whether the ﬁeld has indeed fallen short of its
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responsibilities in this respect, and if so, how things can be improved.
In this paper, we aim to answer both questions. In the next three
sections, we will ﬁrst examine how offspring safety considerations
did or did not play a role in the history of introducing new ARTs.
We do so by presenting three case studies: two from the past, ICSI
and preimplantation genetic testing (PGT), and one contemporary,
mitochondrial replacement therapy (MRT). Based on the ﬁndings, we
will then move on to address the ethical question in the Discussion
section.
Intracytoplasmic sperm injection
Technique
ICSI is a form of IVF whereby a single sperm cell is directly injected
into an egg cell, which makes it possible for men with substantially
low sperm quality to have genetically related children. The ﬁrst
human births resulting from ICSI were reported in 1992 (Palermo
et al., 1992). Soon thereafter, the majority of IVF centers worldwide
adopted the technique (Harper et al., 2012). ICSI can not only be
performed with ejaculated sperm (regular ICSI) but also with medically
extracted sperm either from the epididymis (micro-epididymal sperm
aspiration, MESA) or from the testicles (testicular sperm extraction,
TESE).
Offspring safety risks
The most relevant concerns about ICSI were 2-fold. Firstly, it was
feared that the mechanical perforation of the egg cell might lead to
oocyte injury or lysis (Laufer et al., 1983). Secondly, several authors
suggested that the sperm cells used in ICSI could have genetic abnor-
malities because the technology involves bypassing the mechanism of
natural selection. It was thought that this might affect the health of
the offspring conceived through this technique (Cummins and Jequier,
1994, 1995). For MESA and TESE speciﬁcally, there were also health
concerns due to the risk that the sperm cells used might be old or
not fully matured (Martin-Deleon et al., 1973; Cummins and Jequier,
1995; Küpker et al., 2002). Older sperm cells show relatively high
DNA damage, which might result in embryonic death or, in some
cases, offspring abnormalities (Martin-Deleon et al., 1973; Cummins
and Jequier, 1994, 1995). The use of not fully matured sperm cells,
potentially disrupting the genomic imprinting of the sperm cells, might
lead to embryonic death, growth retardation, birth defects and func-
tional disorders (Cummins and Jequier, 1995).
Safety considerations in strategies of introduction
Hardly, any experimental studies were performed prior to the broad
introduction of ICSI. Firstly, it was assumed at the time that test-
ing ICSI in animal models was not technically feasible. Secondly, the
accidentally discovered technology proved an immediate success in
terms of helping couples with male infertility to have genetically related
healthy children (Dondorp and deWert, 2011). As a result, ICSI quickly
proliferated in clinical practice with clinics often applying conditions,
such as avoiding the selection of immotile sperm, in order to reduce
possible risks. MESA and TESE soon became part of clinical practice in
most countries as well. An exception to this picture was the decision
of Dutch IVF professionals to withdraw MESA and TESE from clinical
application in view of the theoretical risks of these forms of ICSI,
eventually leading to a national moratorium on MESA and TESE (Dutch
Health Council, 1996), that was soon enacted into law. Lifting the
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moratorium would require animal studies providing a better under-
standing of the potential risks for the offspring. When reassuring data
became available from animal research, sperm cell studies and clinical
practice abroad, MESA (2000) and TESE (2007) were again allowed in
the Netherlands, but only in a clinical research setting involving data
collection and follow-up (Kremer and Visser, 2008). The moratorium
was fully lifted only in 2012 (for MESA) and 2014 (for TESE).
Although most commentators stressed the importance of follow-up
research as part of the introduction of new ARTs, not many centers
actually conducted follow-up of children conceived through ICSI. A
notable exception to this was the pioneering center at Brussels Free
University Hospital (Bonduelle et al., 1994, 2004, 2005; Leunens et al.,
2007; Belva et al., 2011, 2016).
State of the art and current practice
It has since been established that ICSI does not lead to major abnor-
malities in offspring (Leunens et al., 2007; Pereira and Palermo, 2018).
However, male subfertility has been associated with defects in the Y-
chromosome. As these chromosomal defects are inherited by male
offspring, it has been shown that boys conceived after ICSI more often
also have lower sperm quality (Belva et al., 2016). Additionally, ICSI is
associated with a signiﬁcantly increased risk of (very) preterm delivery
(Wisborg et al., 2010), lower mean birthweight (Bonduelle et al., 2004)
and an increased risk of rare imprinting disorders (Lazaraviciute et al.,
2014) in comparison to spontaneous conceived and non-IVF ART
pregnancies. Yet, more studies are needed to investigate whether
these speciﬁc health effects are caused by the technique itself or by
other factors, such as underlying paternal conditions (Devroey and Van
Steirteghem, 2004; Berntsen et al., 2019). This is especially important
in view of the fact that ICSI is increasingly offered for all causes of
subfertility (Nyboe Andersen et al., 2008; Boulet et al., 2015; Harris
et al., 2016), albeit without data showing it to be more effective than
conventional IVF for conditions other than male fertility problems
(Van Rumste et al., 2004; Li et al., 2018). In the light of possible
differences in the risk proﬁles of both techniques, this indication
creep is another instance of how safety and effectiveness considera-
tions are both relevant for determining the proportionality of assisted
reproduction.
Preimplantation genetic testing
Technique
PGT enables the selection of embryos based on an evaluation of
their genetic composition. PGT for monogenetic disorders (PGT-M)
and PGT for structural rearrangements (PGT-SR) are indication-based
applications aimed at helping couples at high risk to prevent transmitting
a serious genetic disease to their offspring. These two types (historically
referred to as PGD) were introduced in the late 1980s (Handyside
et al., 1990). The third type, PGT for aneuploidy (PGT-A) was intro-
duced to screen the chromosomal constitution of IVF-embryos with
the aim of increasing the chances of achieving a successful pregnancy.
This was historically called PGS and was introduced in 1995 (Verlinsky
et al., 1995).
The biopsy needed to perform PGT can take three different forms.
Polar body biopsy is rarely used. It only offers information on the
maternal contribution to the genome of the embryo. In blastomere
biopsy (historically the most frequently used biopsy type), one or two
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blastomeres are removed from a cleavage stage embryo at 3 days post-
fertilization (approximately 8 cells). In trophectoderm biopsy, several
cells are removed from a blastocyst stage embryo at 5 days post-
fertilization (150–300 cells).
Offspring safety risks
The main safety concern of PGT is the biopsy needed to collect cells
for genetic testing. There are three possible risks associated with PGT
biopsies for offspring thus conceived. First, there is the risk of the
biopsy procedure itself. The use of a laser, additional actions outside an
incubator or speciﬁc embryo culture media may have risks for the child
conceived after PGT. For example, there is evidence that the use of
speciﬁc embryo culture media affects important offspring parameters
such as birthweight (Zandstra et al., 2015).
Second, the removal of cells may have risks for the development
of the embryo. Early studies in mice and humans have shown an
association of blastomere biopsy with impaired implantation potential
and reduced/delayed fetal development (Tarín et al., 1992; Liu et al.,
1993; Tarín and Handyside, 1993). In recent years, the ﬁeld is shifting
to favoring trophectoderm biopsy over blastomere biopsy (Scott et al.,
2013; Zacchini et al., 2017). A main reason for this is the increased
popularity of PGT-A in many countries, and the aim of overcoming its
diagnostic difficulties due to mosaicism when using blastomere biopsy.
Trophectoderm biopsy may seem less risky at ﬁrst glance, as the biopsy
does not affect the inner cell mass, of which the cells later form the
fetus. In the past, it was thought that ‘the loss of a few mural trophec-
toderm cells should not be important embryologically, since this tissue
does not seem to play a fundamental role in the later development of
the embryo’ (Edwards and Hollands, 1988). More recently, however, it
is speculated that removing these cells could result in a smaller placenta,
which could lead to incorrect embryo development and abnormalities
in offspring (Zacchini et al., 2017; Zhang et al., 2019).
Third, for trophectoderm biopsy, the embryo needs longer in vitro
culturing than for blastomere biopsy (5 instead of 3 days). The effect
of extended embryo culture is still under discussion and thus far little
data are available (Youssef et al., 2015). However, as the use of
speciﬁc embryo culture media affects important offspring parameters
such as birthweight (Zandstra et al., 2015), longer embryo culturing
may further increase these risks. Additionally, cryopreservation may be
necessary more often. Singleton pregnancies following frozen embryo
transfer are associated with higher risk of high birthweight babies
compared with those from fresh embryo transfer (Maheshwari et al.,
2018a), although the interpretation of this ﬁnding has led to some
debate (Somigliana et al., 2018; Maheshwari et al., 2018b). Yet, data on
cryopreservation in combinationwith PGT-A speciﬁcally are still limited
(Penzias et al., 2018).
Safety considerations in strategies of introduction
Prior to the introduction of PGT, preclinical research has been per-
formed, particularly in the mouse model (Gardner, 1985; Monk et al.,
1987; Wilton et al., 1989). After its introduction, research continued
in mice, other animal models and human embryos (Takeuchi et al.,
1992; Carson et al., 1993; Pierce et al., 1997). Nevertheless, infor-
mation on biopsy safety was limited (De Vos and Van Steirteghem,
2001).
Only a few safety measures aimed at decreasing possible offspring
safety risks were taken when introducing the new technology. Some
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centers initially recommended their patients to consider prenatal diag-
nosis after PGT (Vandervorst et al., 2000). This was, however, mainly to
conﬁrm the result of the PGT diagnosis. One understanding at the time
was that as biopsy damage would lead to failed implantation, there was
no need for much concern regarding surviving embryos (Edwards and
Hollands, 1988). Still, regulation involving limiting indications for what
was then called PGD to serious conditions was partly also informed
by the notion that possible biopsy risks should be proportional to the
beneﬁts of selective reproduction made possible by the procedure
(De Wert et al., 2014). Similar reasoning may have informed the 2001
decision by the UK Human Fertilization and Embryology Authority
(HFEA) not to allow preimplantation tissue typing, stating that there
were ‘risks arising from embryo biopsy and it was felt that the Ethics
Committee had not taken proper account of the absence of evidence
of no risk’ (House of Commons, 2005). This ‘absence of evidence of
no risk’ has not stood in the way of a rapid global proliferation of PGT-
A. Even after its upgrade from PGS1 (blastomere biopsy and FISH) to
PGS2 (trophectoderm biopsy and assessment of all chromosomes),
evidence for the effectiveness of this procedure is still lacking and
the treatment’s rationale is under discussion (Scott Jr et al., 2012;
Mastenbroek, 2013, 2014; van Loendersloot et al., 2014; Sermon et al.,
2016; Penzias et al., 2018; Popovic et al., 2018; Lawrenz et al., 2019).
Furthermore, although concerns about the safety of blastomere biopsy
(also referring to possible epigenetic effects) are recently stressed by
authors with a stake in promoting PGT-A, there seems less interest
in how the extended embryo culture needed for trophoblast biopsy
may affect the relative risk proﬁles of both biopsy procedures. Yet,
it is well established that culture conditions have an impact on the
epigenetics of developing embryos, which may well be more outspo-
ken when the culture period is longer (Zandstra et al., 2015). Only
few clinical studies have compared blastomere biopsy with trophec-
toderm biopsy (McArthur et al., 2008; Adler et al., 2014; Coll et al.,
2018).
Only a few centers succeeded in conducting follow-up research
on PGT, particularly in combination with blastomere biopsy. One of
the leading groups was again the Free University Brussels Hospital
(Nekkebroeck et al., 2008; Desmyttere et al., 2009; Liebaers et al.,
2009; Beukers et al., 2013; Kuiper et al., 2017).
State of the art and current practice
Follow-up research does not show a higher degree of major abnor-
malities in children born after PGT in comparison with IVF or ICSI only
(Banerjee et al., 2008; Nekkebroeck et al., 2008; Desmyttere et al.,
2009; Liebaers et al., 2009; Heijligers et al., 2018, 2019). Although
children born following PGT-M and PGT-SR in combination with blas-
tomere biopsy do have an increased risk of adverse obstetric and
neonatal outcomes, these seem mainly related to underlying parental
conditions, except for an increased risk of placenta previa (Bay et al.,
2016). It is important to note that follow-up studies investigating the
health of children born after PGT in combination with trophectoderm
biopsy are still very limited.
PGT-A was originally recommended and carried out as an add-on
to IVF for couples with advanced maternal age, repeated IVF failure,
repeated miscarriage and severe male factor infertility. Regardless of
the ongoing debate about its effectiveness, the technique is increasingly
also offered to younger women with a good pregnancy prognosis
(Mastenbroek and Repping, 2014; Penzias et al., 2018).
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Mitochondrial replacement therapy
Technique
MRT is a form of IVF in which the future child’s mitochondrial DNA
(mtDNA) comes from a donor. This technique has been developed
to allow women who carry disease-causing variants in their mtDNA
to prevent passing these onto their offspring (Hyslop et al., 2016;
Greenﬁeld et al., 2017; Zhang et al., 2017). There are several forms
of MRT. In maternal spindle transfer (MST), the spindle-chromosome
complex is transferred from the prospective mother’s oocyte into a
donor oocyte from which the same has been removed. The resulting
oocyte will then be fertilized in vitro. In pronuclear transfer (PNT), the
male and female pronuclei are removed from the recipient’s fertilized
egg prior to their fusing and are inserted into a fertilized donor egg from
which the pronuclei are removed (Craven et al., 2010).
Offspring safety risks
Apart from the risk of not preventing transmission of the disease, the
main concern with MRT is that manipulation of the (fertilized) egg
cell may have adverse effects for the resulting embryo (Adashi and
Cohen, 2017). One study showed that ‘oocytes that had received their
nucleus from a donor were less likely to develop into a blastocyst
than oocytes who had had their own nucleus injected back into them’
(Hyslop et al., 2016). Yet, it is unclear whether this resulted from
suboptimal interaction between the nucleus of the recipient and the
mitochondria of the donor, or from the oocyte cryopreservation
procedure (Eyre-Walker, 2017; Wei et al., 2019).
Safety considerations in strategies of introduction
In comparison with ICSI and PGT, preclinical research on MRT was
more extensive and more structured. The relevant studies were per-
formed in animals (including nonhuman primates) and human embryos
(Tachibana et al., 2009, 2013; Craven et al., 2010; Paull et al., 2013).
The UK, in particular, has much invested in this research, as it was a
precondition for the government to lift legal restrictions and for the
HFEA to grant a clinical license. Although many research steps were
aimed at improving efficiency, some of them also concerned improving
safety, such as studies of epigenetic modiﬁcations and gene expression
in embryos derived from PNT and MST (HFEA, 2016).
Approaches of introducing MRT vary widely. In 2003, a collaboration
between a Chinese group and a team from the USA reported the ﬁrst
PNT (Zhang et al., 2016). The attempt resulted in the death of two
fetuses after selective fetal reduction. This ultimately led to the USA
and China imposing prohibitive regulatory policies, which still stand
today (Ishii, 2018; Ishii and Hibino, 2018). In 2016, US-based scientists
succeeded in delivering the ﬁrst baby as a result of MST (Zhang et al.,
2017). The procedure was performed in a clinic in Mexico to avoid the
prohibitory policy of the USA. Since then, pregnancies and births using
MRT have also been reported in Ukraine for cases of embryo arrest
(PNT) and in Greece/Spain to overcome female infertility (MST), again
making use of the lack of appropriate regulation (Ishii and Hibino,
2018). In 2015, the UK lifted legal restrictions banning the clinical use
of MRT; however, only for licensed clinics under strict conditions, as
formulated in scientiﬁc reviews conducted by the HFEA. For example,
MRT should only be offered to women who have a signiﬁcant risk
of transmitting a serious mitochondrial disease and where PGT is no
alternative (HFEA, 2015). Additionally, in order to eliminate the risk of
the disease re-emerging in subsequent generations, it is recommended
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that any female born following MST or PST should be advised to
use PGT if she wishes to have children of her own (HFEA, 2013).
In 2017, the HFEA awarded a Newcastle group the ﬁrst UK clinical
license, which resulted in their ﬁrst patient in 2018. This group has
accepted various women with different indications, but so far, no
pregnancy has been reported. In line with HFEA recommendations,
the Newcastle group aims to perform follow-up studies. However,
whereas those recommendations insisted on long-term follow-up, for
practical reasons, the current aim is limited to gathering follow-up data
until the age of 18 months only.
State of the art and current practice
As births following MRT are still very limited and no follow-up data are
available, hardly any conclusions can be drawn regarding the effects in
children thus conceived. Recently, several fertility centers worldwide
have started offering MRT also as a means of ‘rejuvenating’ the eggs
of older women with the promise of increasing their chances of a
successful pregnancy, an idea probably inspired by ooplasmic transfer
in the 1990s (Cohen et al., 1998). The recently reported life births
after MRT in Greece and Ukraine were an instance of this (Devlin,
2019). This premature widening of indications has led ESHRE to issue
a strong condemnation, discouraging the use of MRT for fertility
problems ‘until this technology has been proven to be effective and
safe’ (ESHRE, 2019). Although MRT for fertility problems may be less
risky as carry-over is no issue here, the point remains that, due to
a lack of evidence on effectiveness, there are no proven beneﬁts to
outbalance the remaining risks.
Discussion
Our case studies provide important context for the increasingly louder
claim that, until now, responsible innovation has not been a sufficiently
high priority for the ﬁeld. Where precisely and in what sense might
the ﬁeld have fallen short and, if so, what follows in terms of possible
lessons for the future? To answer this, we make use of Per Sandin’s
four dimensions relevant to dealing with uncertain risks. He presents
these in the context of his discussion of the so-called ‘precautionary
principle’. Following Sandin, the general structure of the precautionary
principle can be reproduced as: ‘If there is (1) a threat, which is (2)
uncertain, then (3) some kind of action (4) is mandatory’ (Sandin,
1999). Using these dimensions as a heuristic tool allows us to zoom
in on the reasoning behind speciﬁc choices made with respect to
introducing new ARTs.
It is important to note that using the four dimensions in this way does
not in itself entail a commitment to accepting the precautionary prin-
ciple as a framework for introducing new ARTs. In fact, the so-called
innovation principle, where ‘the call is for the beneﬁts of innovation to
be weighed against known harm’ (Read and O’Riordan, 2017), can be
understood as dealing with the same issues. The innovation principle
provides, however, a different answer at the crucial juncture where the
precautionary principle links the uncertainty dimension with a need to
take action. By insisting that only ‘known’ harm can be a ground for
limiting the application of new technologies, the innovation principle
emphasizes the importance of unhindered innovation, of which the
beneﬁts would be frustrated by unnecessary measures of precaution.
As our case studies suggest, it would be difficult to maintain that
the ﬁeld has failed to recognize that new ARTs, involving untested
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ways of handling human gametes and embryos, come with possible
risks for children thus conceived. In each of the three case studies,
there has been quite some discussion of the fact that the then new
technology in question (ICSI and its variants, PGT andMRT)might have
adverse consequences for the health of the offspring of the applicants.
In most cases, concerns about possible offspring risks related to the
application of those technologies were hypothetical and had not (yet)
been substantiated. Therefore, any account of how risky precisely a
new technology was had to include an emphasis on the uncertain
nature of the threat, both regarding its chances of materializing and
the seriousness of the possible impact this might have on the health of
children thus conceived.
There is a range of possible ways of dealing with this uncertainty. On
the one end of the spectrum, supporters of the innovation principle
may reason that any measures to constrain the introduction of new
ARTs or to limit their application for safety reasons should be based
on evidence of a signiﬁcant chance that serious harm could other-
wise occur. This view might invite moving new technologies to the
clinic without costly and time-consuming preclinical safety studies and
refraining from setting safety-related restrictions as long as children are
born healthy and no calamities ensue. Some degree of such ‘innovation
principle-reasoning’ may have contributed to the rapid introduction of
ICSI in the absence of preclinical safety studies for which a suitable
animal model was not available at the time.
On the other end of the spectrum, strong versions of the precau-
tionary principle insist on the opposite: as long as new reproductive
technologies pose an uncertain threat to the health of future children,
they should not be introduced. Although we did not encounter explicit
references to the precautionary principle in our case studies, the Dutch
moratorium on clinical applications of MESA and TESE seems a good
example of strong precautionary principle-reasoning, and perhaps the
same can be said of the US Food and Drug Administration’s decision
to ban clinical research of MRT pending safety concerns.
If the innovation principle stands for giving innovation a green light in
the face of uncertainty, and strong versions of the precautionary prin-
ciple would stand for giving it a red light, the intermediate, or weaker,
forms of the precautionary principle may be understood as inviting
an amber light policy, allowing innovation to ‘proceed with caution’.
What characterizes these as forms of the precautionary principle is
their insistence that uncertainty should not be taken as a reason for
refraining from safety measures (Sandin, 1999). However, in order
to be proportional, these measures do not have to be prohibitive.
Using examples from our case studies, relevant measures can, ﬁrstly,
take the form of research aimed at reducing uncertainty both through
preclinical studies using animals and/or human embryos (as in the MRT
case) and through systematic long-term follow-up (as done by the
pioneering ICSI center in Brussels). Secondly, further measures may
include speciﬁc restrictions aimed at reducing avoidable risks in the
application of the relevant technology. Examples from our case studies
include the requirement of using motile sperm for ICSI or setting strict
indications for the ﬁrst clinical applications. A more generally relevant
consideration in this respect is that most couples seeking medically
assisted reproduction (MAR) are subfertile rather than infertile. This
means that in many cases ‘tailored expectant management’ will help in
avoiding unnecessaryMAR in those who do not need fertility treatment
yet (Eijkemans et al., 2017). Avoiding overtreatment is important not
only for economic reasons but also in view of reducing avoidable
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burdens and risks, including offspring risks (Kersten et al., 2015). Finally,
a ‘proceed with caution’ approach would recommend against piling up
procedures with uncertain risks, as in the suggestion at the time of
introducing ICSI to use the then still new PGT technology for checking
the genetic health of ICSI-embryos (Morris and Gleicher, 1996).
In each of our case studies, we found instances of expanding the
use of a potentially risky technology to applications for which its effec-
tiveness has not been proven. This applies to the increasing tendency
of offering ICSI for non-male fertility problems, to the widespread use
of PGT-A as a general add-on to IVF and to recent reports about MRT
being offered for oocyte rejuvenation and embryonic arrest. Instead of
taking safety as an absolute criterion, assessing whether a technique is
safe enough is rather a matter of proportionality. By using a potentially
risky technique for indications that lack evidence of effectiveness,
those risks do not weigh up against the beneﬁts. While it may be an
open question whether the innovation principle could be invoked for
justifying these practices (does the principle allow ignoring uncertain
risks also if there are no proven beneﬁts that might be frustrated by
restrictive measures?), it is clear that these unproven expansions are
squarely at odds with even the weakest versions of the precautionary
principle.
Although our case study analysis suggests that it would be wrong
to conclude that responsible innovation has not been a concern of
the ﬁeld, it is also clear that this has not been a systematic and
shared endeavor of the ﬁeld as a whole. Relevant ESHRE guidance
(Pennings et al., 2007; Provoost et al., 2014) seems to be taken by
fertility centers as expressing non-committal suggestions rather than
stating shared professional responsibilities. Clearly, this should not be
a problem if the innovation principle is to determine what counts as
responsible innovation. While that may sound quite attractive in a
ﬁeld that to a large extent is driven by commercial interests, it is not
a tenable position from an ethical point of view. As acknowledged
by ESHRE, professionals working in human reproduction inevitably
assume a responsibility to take account of the welfare of the children
they are causally involved in creating (Pennings et al., 2007). As it
seems that what we have referred to as weaker forms of precautionary
principle are best able to capture this double responsibility, it is crucial
that the corresponding approach to responsible innovation should not
remain a pious wish. In terms of what Sandin refers to as the ‘command
dimension’ of dealing with uncertain risks, our case studies suggest
that without the backing of legal frameworks (such as those governing
the introduction of MRT in the UK), current professional guidance
lacks sufficient commanding power to ensure that new technologies are
not introduced without research efforts aimed at reducing uncertainty
about the nature and magnitude of offspring risks.
Inevitably, this leads to the question of what the threshold for
acceptable risk should be. Clearly, the view that MAR is only acceptable
if it leads to perfectly healthy children lays the bar too high. Not only
does all reproduction come with risks, the trade-offs relevant to MAR
are different from those in natural reproduction. However, the fact
that some patients are desperate enough to accept even high risks
for the child-to-be rather than remain childless does not mean that it
should be left to individual patients or couples to determine what risks
are still acceptable. As elsewhere in medicine—and even more so in
MAR-given professional co-responsibility for the welfare of the child—
informed consent is a necessary, but not a sufficient, condition for what
might count as responsible treatment (Dondorp and De Wert, 2011).
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According to ESHRE’s Task Force on Ethics and Law, the bottom line
is that assisted reproduction should not entail a high risk that the child
would have a seriously diminished quality of life (Pennings et al., 2007).
Still, more debate seems needed on the most appropriate criterion for
acceptable risk in the context of introducing new ARTs.
Conclusion and recommendations
In each of our case studies, offspring safety concerns have been on the
agenda of the debate about bringing the relevant technologies to the
clinic. However, apart from settings where this was legally required,
systematic safety and effectiveness studies (in line with ESHRE guid-
ance) were not always conducted. One possible reason for this is the
different views about how to deal with the uncertain (often theoret-
ical) nature of the risk. As we have argued, an innovation principle
approach seems at odds with the notion that professionals in assisted
reproduction have a responsibility to take account of the welfare of
the children they are creating. While strong (prohibitive) forms of the
precautionary principle seem difficult to justify in the light of the equally
morally important interests of those dependent on medical help for
having children, we suggest a policy of proceeding with systematic
caution.
Although follow-up research has shown that up until now, only few
adverse health effects of new ARTs have emerged, this should not be
taken as a reason for complacency. As new reproductive technologies
are on the horizon that appear to come with potentially signiﬁcant
offspring risks (including the reproductive use of stem cell-derived
gametes or genetically modiﬁed embryos), this should be regarded as
a matter of concern that may require both professional societies and
governments to take a more active role in safeguarding the responsible
development of these technologies. Although this should be primarily
a matter of self-regulation, governments can play an important role
in terms of providing a legal context for such self-regulation and for
ensuring compliance with its provisions.
Finally, more debate seems needed on determining the threshold
for acceptable risk in the context of introducing new ARTs. Multiple
stakeholders, including professional societies and patient organizations,
should have a role in this.
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